Global private equity and venture capital news and research

Aerie’s venture backers eye strong stake valuations from imminent IPO $

22 Oct 2013

The venture capital-backers of eye disease treatment company Aerie Pharmaceuticals all plan to drop their stakes to below 20 per cent through the company’s impending IPO.

Sorry, you have reached your quota of 1 free article a week or you are attempting to read a Premium story. To read more, simply sign-up to our daily newsletter.

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2015